The combination of PS-targeting mAbs with immune checkpoint blockade (anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or anti-PD-1) was evaluated in breast and melanoma syngeneic models of cancer in immunocompetent mice [20,21]. This evidence concerns the gene CTLA4 and melanoma.